INTRODUCTION
The intricate balance between immune defense and inflammation in the gut is a highly regulated process that requires interactions between the intestinal epithelium and the underlying immune system. A breakdown in this balance is believed to promote the induction and perpetuation of the chronic intestinal inflammation found in patients with intestinal inflammatory diseases. 1, 2 Lymphotoxin beta receptor (LTbR), a member of the tumor necrosis factor receptor superfamily of cytokines, has been shown to play a critical role in the regulation of mucosal immune responses. [3] [4] [5] [6] Like many other members of the tumor necrosis factor receptor superfamily, LTbR signaling can mediate both protective and pathogenic effects during intestinal inflammation. While inhibition of LTbR signaling has been shown to be beneficial in a T-cell-mediated colitis model, 7 studies utilizing other chemically induced and infectious colitis models suggest that LTbR signaling plays a protective role against intestinal injury. 4, 5, [8] [9] [10] [11] Additionally, LTbR-dependent production of interleukin-22 (IL-22) by innate lymphoid cells (ILCs) has recently been shown to be essential for protection against the bacterial pathogen Citrobacter rodentium. 4, 10 However, the mechanisms whereby LTbR signaling contributes to protection during epithelial damage remain to be fully elucidated.
ILCs are a heterogeneous population of innate lineagenegative lymphoid cells that rapidly produce several cytokines upon stimulation and participate in the regulation of immunity at mucosal surfaces. [12] [13] [14] The current classification of ILC populations is based on the expression of specific transcription factors that regulate their development and function, and their cytokine profiles. 15 Group 3 ILCs (ILC3s) are dependent on the transcription factors RAR-related orphan receptor gamma t (RORgt) and Gata3 for their development and include CD4 þ and CD4 -lymphoid tissue inducer cell populations (LTi cells), natural killer (NK)p46 þ and colitogenic NKp46 -ILC3s. [15] [16] [17] [18] A protective role for ILC3s during epithelial injury was suggested by a previous study showing that RORgtdeficient mice, which lack all ILC3 subsets, exhibited increased susceptibility to chemically induced colitis. 19 In contrast, a pathogenic role for ILC3s has also been reported in experimental colitis models and in patients suffering from inflammatory bowel disease. 16, 20 However, the mechanisms that regulate the function of distinct ILC3s during mucosal damage are still poorly defined. IL-22, IL-17, and interferon g (IFNg), the principal cytokines produced by ILC3s, have major effects on epithelial cells of many tissues and are critical in defense against mucosal bacterial pathogens. 15, 21, 22 IL-22 has been identified as an important regulator of inflammation, particularly at the barrier surfaces of the skin, lung, and intestine. 14, 23 However, dysregulation of IL-22 signaling may also be associated with disease progression, including tumorigenesis. [24] [25] [26] Therefore, understanding the mechanisms controlling IL-22 production by distinct ILC3s populations during mucosal damage is critical for development of effective disease therapies.
In the present study, we investigate the role of LTbRmediated signaling between intestinal epithelial cells and ILC3s in a model of mucosal wound healing. Our data suggest that during epithelial injury, LTbR engagement in intestinal epithelial cells drives IL-23 production. The IL-23 then induces IL-22 production by CD4
À LTi cells thereby promoting epithelial cell repair and homeostasis. These results support a novel mechanism wherein LTbR-mediated cooperation between epithelial cells and LTi cells regulates intestinal homeostasis to limit mucosal damage.
RESULTS

LTbR signaling protects against intestinal epithelial injury by promoting IL-22-dependent epithelial cell repair and homeostasis
To define the role of LTbR signaling in mucosal wound healing, we utilized an acute epithelial injury regeneration model, induced by transient administration of dextran sulfate sodium (DSS) in the drinking water. Since the genetic background of the mouse can significantly influence the outcome of DSS treatments, 27 we first generated neo-free LTbR-deficient and LTbR-floxed mice by crossing tri-loxP conditional LTbRfloxed mice 4 with ubiquitous MeuCre40 deleter mice, 28 (all on C57BL/6 background) and selecting recombinants with a deletion of the neo cassette (Supplementary Figure S1a , b online). We then treated control neo-free LTbR-floxed mice (Ltbr fl/fl ) and neo-free LTbR-deficient mice (Ltbr D/D ) with drinking water containing DSS for 5 days followed by normal water for 3 days. Compared with Ltbr fl/fl mice, Ltbr D/D mice lost body weight rapidly and displayed reduced survival (Figure 1a,  b) . Consistently, the disease score, assessed daily as an average of body weight loss and signs of rectal bleeding and diarrhea, was increased in Ltbr D/D mice ( Figure 1c) . Importantly, these differences were not associated with altered food or water consumption (Supplementary Figure S1c) . Macroscopic examination of the colons at day 8 revealed severe pathology and significant reduction of colon length in Ltbr D/D mice compared with control animals (Figure 1d) . Additionally, while the colon mucosa and submucosa of Ltbr fl/fl mice exhibited low histological scores reflecting only slight infiltration of inflammatory cells, Ltbr D/D mice exhibited increased histological scores reflecting severe destruction and necrosis of epithelial cells, loss of goblet cells, thickening of the submucosa, and increased infiltration of inflammatory cells (Figure 1e) . Together, these data show that LTbR signaling is essential for mucosal wound healing following epithelial injury.
To define the mechanism whereby LTbR signaling conferred protection against DSS-induced colitis, we measured the expression of genes known to be involved in the induction or regulation of intestinal inflammation at day 5, when the response of the two groups was beginning to diverge. Surprisingly, Ltbr fl/fl and Ltbr D/D mice displayed similar colonic mRNA expression levels for several chemokines (Cxcl1, Cxcl13, Ccl2, and Ccl20), IL-17 family members (Il17a, Il17c, Il17e, Il17f, and Il17re), key pro-inflammatory cytokines (Il-1b, Il6, ifng, and tnf) and regulatory molecules such as Il10 and Trim30a (Supplementary Figure S1d) . However, we found that Il23a and Il22 mRNA expression were significantly reduced in the colons of DSS-treated Ltbr D/D mice (Supplementary Figure S1d ). To define the kinetics of IL-22 production, we next measured Il22 mRNA expression during the injury and regeneration stages of colitis. While DSS-treated Ltbr fl/fl mice displayed a marked upregulation of Il22 mRNA expression in the colon between day 5 and day 8 ( Figure 1f) , Ltbr D/D mice failed to upregulate colonic IL-22 ( Figure 1f, g ), suggesting that LTbR signaling is required for IL-22 production during intestinal injury.
IL-22 has been shown to exert its antiinflammatory effects via the induction of a wide range of antimicrobial peptides that help to prevent the lethal dissemination of intestinal microbiota, and via reinforcing the mucus barrier and enhancing epithelial cell regeneration. [29] [30] [31] [32] Unexpectedly, we found comparable mRNA levels of Reg3b, Reg3g, and Figure 1m) . Moreover, analysis of epithelial cell proliferation following bromodeoxyuridine pulse injection revealed that intestinal epithelial cell proliferation was markedly reduced in Ltbr D/D mice ( Figure 1n ). Collectively, these data suggest that LTbR-mediated IL-22 production promotes intestinal wound healing by inducing the regeneration of the epithelial layer. 
. Taken together, these data suggest that IL-22-mediated induction of mucins is the critical mechanism downstream of LTbR signaling that promotes wound healing after epithelial injury.
LTbR signaling promotes epithelial wound healing through IL-22 production by CD4 À LTi cells
To identify which cells require LTbR signaling for IL-22 production during intestinal injury, we compared Il22 mRNA expression in distinct innate and adaptive cell populations isolated from the colonic lamina propria (LP) of RORgt-green fluorescent protein (GFP)
and RORgt-GFP þ / À Ltbr D/D reporter mice treated with DSS for 5 days. We found that Il22 expression was markedly
, indicating that IL-22 production by these cells is LTbR dependent. Interestingly, Il22 expression by NKp46 þ ILC3 cells was not significantly impaired in the absence of LTbR signaling ( Figure 3a) . Importantly, we found comparable numbers and frequencies of CD4 Production of IL-22 by ILCs has been shown to be triggered by IL-23R stimulation. 21, 22 We found that ILCs and RORgt Ltbr / +pRK Ltbr / +IL-22 were poor producers of IL-17A or IFNg (Figure 3e) (Figure 3e ). Remarkably, we found that the frequency of IL-22-producing CD4 À LTi cells was higher than the frequency of IL-22-producing CD4
þ LTi cells (77.2% vs. 22.8%, respectively) (Figure 3e) , suggesting that CD4
À LTi cells represent a predominant source of IL-22 during epithelial injury.
To further delineate the contribution of CD4 À and CD4 
CD4
þ LTi cells or both CD4 À and CD4 þ ILCs, respectively.
Depletion of Thy1
þ ILCs in DSS-treated Rag1 À / À mice induced severe pathology and dramatically reduced colonic IL-22 expression (Figure 3f-i) . In contrast, anti-CD4 treatment only partially reduced colonic IL-22 expression, yet it had no effect on mortality, body weight loss, or colon shortening in DSS-treated Rag1 À / À mice (Figure 3f-i) , suggesting that although CD4
þ LTi cells may contribute to LTbR-mediated IL-22 production during intestinal injury, they are dispensable for protection. Collectively, these results suggest that LTbR signaling promotes epithelial wound healing through the induction of IL-22 production by CD4 À LTi cells.
LTbR signaling in epithelial cells protects against intestinal epithelial injury by promoting IL-23-driven IL-22-dependent tissue protective responses
To identify which LTbR-expressing cells are essential for controlling IL-22 production during epithelial injury, we generated reciprocal bone marrow chimeric mice. Following DSS treatment, we observed reduced survival, increased body weight loss, and reduced colonic IL-22 expression in wild type (WT)-Ltbr D/D and to a lesser extent in Ltbr D/D -WT chimeras with respect to WT-WT chimeras (Figure 4) , indicating that LTbR expression on both radio-resistant cells and bone marrow-derived cells contributes to protection against epithelial injury. Additionally, mice lacking LTbR in CD11c þ cells (CD11c-Ltbr À / À ) displayed increased body weight loss, reduced survival, and reduced colonic IL-22 levels (Supplementary Figure 3) , indicating a role for LTbR signaling in dendritic cells (DCs) in protection against epithelial injury, in line with previous studies in an infectious colitis model. 10 Since WT-Ltbr D/D chimeras displayed increased morbidity and colon pathology compared with WT-WT chimeras (Figure 4) , we hypothesized that LTbR signaling in intestinal epithelial cells maybe important for IL-22-mediated wound healing after epithelial injury. To test this, we generated mice with specific inactivation of LTbR in epithelial cells (Vil-Ltbr À / À mice). Compared with Ltbr fl/fl mice, DSS-treated Vil-Ltbr À / À mice displayed increased body weight loss, reduced survival, reduced colon length, and severe colon inflammation (Figure 5a-d Figure S4) , suggesting that the migration or expansion of these cells to the LP during DSS-induced injury is not impaired in the absence of LTbR signaling in epithelial cells. However, epithelial cell proliferation and the expression of the antiapoptotic factors Bcl2 and Bclxl were significantly reduced in the colons of Vil-Ltbr To determine which cells produce IL-23 during DSS-induced epithelial injury, we generated bone marrow chimeric mice using WT and Il23a À / À mice 36 and treated them for 5 days with DSS. Unexpectedly, we found that colonic Il23a mRNA expression was comparable in WT-WT and Il23a-WT mice whereas it was greatly reduced in WT-Il23a À / À mice ( Figure  6a) . These results suggest that Il23a is mainly produced by radio-resistant cells in WT mice during DSS-induced colitis. We also observed that WT-Il23a À / À mice displayed increased pathology with significant reduction of colon length and increased disease score after DSS treatment, compared with WT-WT and Il23a-WT chimeras (Figure 6b) , suggesting that Il23a expression by radio-resistant cells contributes to protection against intestinal inflammation.
To further define the cell types responsible for IL-23 production following epithelial injury, we induced colitis in IL-23-GFP þ / À reporter mice. 36 Surprisingly, we found that IL-23-driven GFP expression was upregulated in epithelial cells, as well as DCs and macrophages (Figure 6c and Supplementary Figure 5 ) at day 5 post DSS treatment, indicating that epithelial cells are capable of producing IL-23 during epithelial injury. Furthermore, inhibition of LTbR signaling using an LTbR-Ig fusion protein reduced both IL-23-driven GFP and colonic Il23a and Il22 mRNA expression (Figure 6c, d) , suggesting that LTbR signaling promotes IL-23 production by epithelial cells during mucosal damage. In contrast to LTbR-Ig treatment, activation of the LTbR pathway using agonistic aLTbR antibody was able to upregulate colonic Il23a and Il22 expression during epithelial injury (Figure 6e) .
To confirm the ability of LTbR signaling to directly induce IL-23 production by epithelial cells, we stimulated both trans- 6f, g), suggesting that direct activation of LTbR on epithelial cells can induce IL-23. Furthermore, IL-23 production was also induced after stimulation with lipopolysaccharide (Figure 6f, g ), indicating that epithelial cells can produce IL-23 in response to toll like receptor 4 agonists. Consistently, Il23a expression was reduced in purified colon epithelial cells of Vil-Ltbr À / À mice during DSS-induced injury (Figure 6h) . Together, these data indicate that LTbR signaling in intestinal epithelial cells promotes IL-23 production during mucosal damage.
Given that IL-23 is composed of p19 (Il23a) and p40 (Il12b) subunits, we then investigated the ability of epithelial cells to induce IL12b expression during DSS-induced injury.
IL12b expression was upregulated in both purified colonic epithelial cell fraction and sorted colonic epithelial cells (Supplementary Figure 6a, b) . To further define the role of Il12b production by radio-resistant cells in mucosal protection, we generated reciprocal bone marrow chimeric mice. Although both radio-resistant and bone marrow-derived cells contributed to Il12b expression during DSS-induced injury, mice lacking Il12b in radio-resistant cells displayed increased disease score, reduced colon length, and reduced colonic IL-22 production during DSS-induced injury ( Supplementary Figure 6c-f) . These results indicate that Il12b can be expressed by epithelial cells and participate in 
CCR6
þ T-bet -LTi cells. The IL-22 then induces intestinal epithelial cell proliferation and survival, and the production of mucus thereby promoting mucosal wound healing. These results provide evidence that support a novel mechanism of protection against intestinal injury in which the LTbR-dependent production of IL-23 by epithelial cells regulates mucosal wound healing.
IL-23 is critical for IL-23R-mediated production of IL-22 by ILCs. 21, 22 A dichotomy between beneficial and pathogenic roles for IL-23R-responsive innate and adaptive cell populations has been described in the DSS-induced colitis model. 37, 38 DCs and macrophages are thought to be the major IL-23 producers during infection, inflammation, and cancer progression in the colon, although epithelial cells can also contribute to IL-23 production.
39-42 Accordingly, we have previously demonstrated that LTbR-mediated production of IL-23 by DCs promotes IL-22 production by RORgt þ ILCs during mucosal bacterial infection. 10 Additionally, our results using CD11c-Ltbr À / À mice suggest that LTbR signaling in DCs contributes to protection against DSS-induced injury. Unexpectedly, in the current study, we find that IL-23 and IL-22 production during epithelial injury are impaired in the absence of LTbR signaling in intestinal epithelial cells. We demonstrate that activation of LTbR signaling can promote IL-23 production by epithelial cells, identifying a previously unrecognized mechanism of LTbR-dependent regulation of intestinal wound healing. Our results indicate that both p19 and p40 subunits of IL-23 can be expressed by epithelial cells during DSS-induced injury. These results suggest that following epithelial damage, epithelial cells represent an important source of IL-23 for mucosal repair.
LTbR signaling is known as a key regulator of lymphoid organ development and maintenance; however, its function outside of lymphoid organs is still elusive. In the present study, we reveal that LTbR signaling in intestinal epithelial cells is essential for IL-22 production by RORgt þ ILC3s. Although mice with specific inactivation of LTbR in epithelial cells (VilLtbr À / À mice) were highly sensitive to DSS-induced injury, LTbR signaling in other cells could also contribute to protection. Indeed, a protective role for LTbR activation in DCs and macrophages was recently described in infectious and chemically induced colitis models. 4, 9, 10 Recent studies have implicated the role of the gut microbiota in the pathogenesis of intestinal inflammation. þ ILC3s represented less than 5% of IL-22-producing ILC3s, and IL-22 production by those cells was LTbR independent, in agreement with previous results. 46 A recent study suggested a critical role for CD4
þ LTi cells in IL-22-mediated protection against infectious colitis, 47 whereas the function of CD4 À LTi cells in mucosal homeostasis remained obscure. Unexpectedly, we found that depletion of CD4 þ LTi cells in Rag1 À / À mice only partially reduced colonic IL-22 levels but had no effect on colon immunopathology and mice survival, indicating that CD4 þ LTi cells are not critical for protection against DSS-induced intestinal injury. This observation might be explained by the fact that the vast majority (approximately 75%) of IL-22-producing LTi cells did not express CD4. Therefore, our results suggest that CD4 -LTi cells are the main producers of IL-22 during epithelial injury. Since the developmental plasticity between RORgt þ ILC subsets remains controversial, 15, 17 it is important to determine the role of LT in the regulation, and function of CD4 -and CD4 þ LTi subsets in future studies. Increased LT expression has previously been found in the mucosa of inflammatory bowel disease patients. 48 Additionally, chronic overexpression of LT, as a transgene, has been connected with the formation of tertiary lymphoid tissue, chronic inflammation, immunopathology, and tumor progression. 49 Therefore, future studies will be required to better define whether LT expression by distinct ILC populations correlates with disease severity in human inflammatory bowel disease patients. In summary, our findings suggest that the LTbRdependent IL-23 production by epithelial cells limits mucosal damage via induction of IL-22 by CD4 -LTi cells and that the manipulation of LTbR signaling may represent a novel therapeutic avenue in inflammatory diseases of the intestine.
